AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02209922 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: Participants underwent tDCS(2mA) brain stimulation (20 minutes) and simultaneous balance training(20 minutes) for 5 consecutive days,for 1 week.
Study NCT02209922 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: During sham stimulation, the current ramped up for 30 seconds, ramped back down for 30 seconds, and then remained off for the duration of the stimulation then and simultaneous balance training(20 minutes) for 5 consecutive days,for 1 week.
Study NCT02142556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of quetiapine XR
Description: The treatment was initiated with a 7-day cross-titration period. Previous antipsychotic medication was maintained at the original dose from day 1 to day 3; then reduced to 50% of the original dose from day 4 to day 7 and discontinued on day 8. Meanwhile, the patients started quetiapine XR with daily dose at 300 mg on day 1, 600 mg on day 2 and up to 800 mg after day 2. From day 8 until the end of the study, the dose of quetiapine XR was adjusted within 400-800 mg per day, depending on the clinical response and tolerability of the patients.
Study NCT02490163 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectra Optia
Description: The Spectra Optia® Apheresis System is an automated centrifugal system that separates whole blood into its cellular and plasma components. The device is comprised of three major sub-systems, 1) the apheresis machine itself, 2) a sterile, single-use, disposable blood tubing set, and 3) embedded software.~Terumo BCT developed a completely automated apheresis system: the Spectra Optia MNC and CMNC based on an automatic interface-controlled technology that allows MNCs collection without the intervention of an operator. The optical sensors continuously control and adjust the buffy coat layer by adjusting the plasma flow.~The Spectra Optia MNC collects MNCs by intermittent flow: MNCs accumulate and are flushed from a secondary chamber at intervals during the procedure. On the other hand, the very recently released Spectra Optia CMNC (developed especially to collect stem cells that reside in the MNCs layer) is able to collect MNCs by continuous flow.
Study NCT01478646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional breathing therapy
Description: duration: 60 minutes.
Study NCT01478646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reflectory breathing therapy
Description: duration: 60 minutes.
Study NCT03200951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bolus group for epidural block
Description: Randomly selected patients of the bolus group are given 0.3 ml/kg bolus of 0.15% ripivacaine for epidural block.
Study NCT03200951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infusion group for epidural block
Description: Randomly selected patients of the infusion group are given 0.3 ml/kg/hr 0.15% ripivacaine for epidural block.
Study NCT03376633 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working on Womanhood (WOW)
Description: A trauma-informed group counseling and clinical mentoring intervention for young women
Study NCT02725489 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vigil
Description: Vigil is made up of irradiated autologous tumor cells which have been electroporated ex vivo with the Vigil plasmid designed to suppress expression of both the TGFβ1 and TGFβ2 proteins while simultaneously expressing rhGMCSF protein.
Study NCT01245647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone, 50mg, once per day for 4 months
Description: Naltrexone: Two thirds of the total study participants will receive the medication naltrexone. Each study participant will take a single pill once a day for 4 months.
Study NCT01245647 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill, 50mg, once per day for 4 months
Description: Placebo: One third of the participants will receive placebo pills that look the same as the active comparator but are really just inert pills. Each study participant will take a single pill once a day for 4 months.
Study NCT02370121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules of 300 mg two times per day before breakfast and dinner a total dose of 600 mg per day. During 90 days.
Study NCT02370121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gymnema Sylvestre
Description: Capsules of 300 mg of calcined magnesium two times per day before breakfast and dinner a total dose of 600 mg per day. During 90 days.
Study NCT01771926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: potatoes
Description: Daily intake of assigned treatment for 8 weeks
Study NCT01771926 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: other carbohydrate
Description: Daily intake of assigned treatment for 8 weeks
Study NCT03423771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPF-08
Description: Drug: NPF-08 Arms: NPF-08 oral sulfate solution
Study NCT02725489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: A human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody directed against programmed cell death ligand 1 (PD-L1)
Study NCT01532193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decreased oxygen concentration
Description: The oxygen concentration is decreased during the in Vitro embryo culture.
Study NCT00603772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atralin (tretinoin) gel, 0.05%
Description: Assess photoallergic reactions for tretinoin 0.05% and vehicle, measured as skin reactions following induction and challenge.
Study NCT00126880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVX754
Description: apricitabine, 600mg BID or 800mg BID
Study NCT00126880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3TC
Description: 3TC, 150mg BID
Study NCT03099343 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Location-based Tailored Messaging
Description: The mobile application works by providing tailored messages targeted to participant locations that can help individuals to choose lower sodium foods.
Study NCT01695278 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Counseling
Description: Weekly telephone counseling intervention for 16 weeks, used to identify and overcome barriers to diabetes control and set goals for positive behavioral changes supplemented by monthly group classes on skill development.
Study NCT01695278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counseling
Description: Weekly telephone counseling intervention for 16 weeks, used to identify and overcome barriers to diabetes control and set goals for positive behavioral changes supplemented by monthly group classes on skill development.
Study NCT02575066 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: external beam radiotherapy
Description: external beam radiotherapy 25 x 2 Gy / 18 x 2 Gy
Study NCT02575066 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: pazopanib
Description: pazopanib QD 800 mg
Study NCT02239120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: optional ASA as comedication
Description: optional concomitant treatment which can be used for patients with coronary artery disease. It is not required for these pts.
Study NCT02239120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to ASA
Description: placebo to comparator drug
Study NCT02239120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to optional ASA as comedication
Description: optional concomitant treatment which can be used for patients with coronary artery disease. It is not required for these pts.
Study NCT02239120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to dabigatran etexilate
Description: placebo
Study NCT02239120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA 100 mg
Description: active comparator drug
Study NCT02239120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: active drug
Study NCT02213133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor (KPT-330)
Description: Oral tablet or suspension at 60, 80, 100 or 120 mg per patient-specific body surface area category. Dosing will occur twice weekly in 28-days cycle.
Study NCT03682653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: a single dose of Azithromycin will be administered to infants between their 8-27th days of life
Study NCT03682653 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a single dose of Placebo will be administered to infants between their 8-27th days of life
Study NCT00433888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R744
Description: 100μg/4 weeks for 8 weeks,then 25\~400μg/4 weeks for 40 weeks
Study NCT00433888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R744
Description: 150μg/4 weeks for 8 weeks,then 25\~400μg/4 weeks for 40 weeks
Study NCT01587989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: 15-25 mg orally weekly, Weeks 1-12
Study NCT03172351 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EDoF1
Description: extended depth of focus IOL - EDoF1
Study NCT03172351 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monofocal
Description: Monofocal IOL
Study NCT03172351 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monofocal
Description: Monofocal IOL
Study NCT03641365 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test group
Description: Guided Implant placement Positioning/placement of dental implants thought the fully acrylic surgical template without metallic sleeves.
Study NCT03641365 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Guided Implant placement Positioning/placement of dental implants thought the acrylic surgical template with metallic sleeves.
Study NCT00671060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 200 mcg buccal misoprostol administered every 6 hours for up to 48 hours until fetus is delivered.
Study NCT00671060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Description: 100 mcg buccal misoprostol administered every 6 hours for upto 48 hours
Study NCT01773369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early leg training
Description: Children will engage in \~1 hour/day, 4 days/week treatment for 3 months. The treadmill will consist of supported walking on a treadmill, over ground, stair climbing, standing, kicking, splashing ... etc. leg activity. Activities will be directed by a physical therapist in the clinical setting.
Study NCT01773369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed leg training
Description: The training activity will be exactly the same as the Early leg training group, except that it will occur \~3 months after recruitment.
Study NCT01773369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent leg training
Description: Children will engage in \~1 hour/day, 4 days/week treatment for 3 months. The treadmill will consist of supported walking on a treadmill, over ground, stair climbing, standing, kicking, splashing ... etc. leg activity. Activities will be directed by parents in their home or community environment.
Study NCT05513911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia
Description: Acute Intermittent Hypoxia is administered in 30-60 second bouts of 9% O2 concentration, followed by 60-90 seconds of normoxic air concentrations (21% O2, room air). This procedure is repeated 15 times for a 30 minute session
Study NCT01503424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine Tablets, 5 mg
Study NCT01503424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine Tablets, 5 mg
Study NCT02016118 — intervention group
Intervention type: DEVICE
Intervention: Ialuril
Description: The treatment is an intravesical administration of combined hyaluronic acid (HA) 1.6% and chondroitin sulphate (CS) 2.0% once per week for the first month, followed by one instillation every two weeks for the second month and one instillation per month until stable remission of the symptoms.
Study NCT01516099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General Practitioners
Description: The general practitioner can refer his patients to a physical activity counselor for an individual coaching (intake session with development of program and pretesting, follow up by e-mail or phone (max 4x), personal contact moments (max 3x) and exit session with evaluation and posttesting).
Study NCT01516099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social-cultural organizations
Description: In the social-cultural organization, members can sign in for group sessions led by the physical activity counselor (intake session with development of program and pretesting, follow up by email or letters (max 4x), personal contact moments (max 4x) and exit session with evaluation and posttesting).
Study NCT03320915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Cholecalciferol 5mg (200,000 IU) up to maximum of three times during 1 year follow-up period according to measured 25(OH)D3 level.
Study NCT01146483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin, Pantoprazole
Description: Rosuvastatin, 10 mg tablets, single dose on the morning~Concomitant drug: Pantoprazole; 40 mg tablets, 2 single doses administered 1 hour before rosuvastatin and 23 hours after rosuvastatin administration. A placebo is given on the other period as a crossover design study.
Study NCT01587989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 15-25 mg orally weekly, Weeks 1-12
Study NCT01587989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: 15-25 mg orally weekly, Weeks 13-24
Study NCT01587989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: methotrexate placebo orally weekly, Weeks 13-24
Study NCT01587989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg iv every 4 weeks, 24 weeks
Study NCT01587989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg iv every 4 weeks, 24 weeks
Study NCT02421250 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radical-7 Noninvasive Hgb Monitor
Study NCT01261403 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDA001
Description: Dose escalation study: Subjects will be assigned to 1 of 2 treatment groups (1 unit or 4 units vs. vehicle control) based on the order in which they enroll in the study. Intravenous infusion will be administered on days 0 and 7. Nonresponders will be unblinded after 12 weeks of study. Non- responders on vehicle control will be re-dosed with the active PDA001 dose assigned at baseline (2 infusions, 7 days apart). Nonresponders taking active PDA001 will enter the safety follow-up portion of the study. Responders at 12 weeks will continue in the safety and efficacy follow-up portion of the study until 12 months of study. Responders will be treated for RA flare between 3-9 months of study with the active PDA001 dose assigned at baseline (2 infusions, 7 days apart).
Study NCT01261403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle Controlled Placebo
Description: Cohort Dose Level 1: 4 units vehicle controlled placebp infused on Day 0 and Day 7~Cohort Dose Level 2: 4 units vehicle controlled placebo infused on Day 0 and Day 7
Study NCT01261403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Controlled Placebo
Description: Cohort Dose Level 1: 4 units vehicle controlled placebp infused on Day 0 and Day 7~Cohort Dose Level 2: 4 units vehicle controlled placebo infused on Day 0 and Day 7
Study NCT02871479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAN007 5% cream
Description: 5% EISO in a cream formulation applied twice a day for up to 28 days.
Study NCT02871479 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo cream containing the same components as the vehicle for the active intervention arm
Study NCT02871479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAN007 10% cream
Description: 10% EISO in a cream formulation applied twice a day for up to 28 days.
Study NCT01725880 — intervention group
Intervention type: OTHER
Intervention: Observation
Study NCT05104944 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Serial MRIs
Description: Serial use of MRI at 3, 6, 9 and 12 months to identify disease resolution and thus discontinuation of immobilisation plus standard care.
Study NCT01331161 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZOSTAVAX
Description: shingles vaccine, one dose
Study NCT03542994 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: EDP1066
Description: EDP1066 is an orally administered monoclonal microbial
Study NCT03172351 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EDoF2
Description: Comparison EDoF2 IOL
Study NCT03172351 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EDoF2
Description: Comparison EDoF2 IOL
Study NCT03542994 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo oral capsule
Description: placebo
Study NCT02760290 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraperitoneal cesarean section
Study NCT02760290 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraperitoneal cesarean section
Study NCT03751332 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tacrolimus
Description: Conversion from either cyclosporin or tacrolimus to tacrolimus modified release
Study NCT02594644 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedle Roller
Description: The study device (MR200, Clinical Resolutions Laboratory, Inc.) is a disposable roller equipped with stainless steel needles that are 650 micrometers in length.
Study NCT02594644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolevulinic Acid
Description: Levulan® Kerastick® DUSA Pharmaceuticals, Inc., Wilmington, MA
Study NCT02594644 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Blue Light
Description: Blu-U unit (DUSA Pharmaceuticals, Inc., Wilmington, MA
Study NCT00960076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: 5mg oral tablet once daily
Study NCT00960076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin XR
Description: 500mg oral tablet once daily
Study NCT00960076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Description: 750mg, 2 tablets once daily
Study NCT00960076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin XR
Description: 750mg, 2 tablets once daily
Study NCT02126059 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminiscence
Description: The 10 session topics include Happy to seeing you, Childhood stories, Food flavor, Our old songs, Festival, My family, My Carrier, Unforgettable events, My home, and My award.~small group intervention (8-12 per group), expected total number of group is 5.
Study NCT02126059 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation
Description: The 10 session topics include psycial activities, sound, face, food, word association, number and games, being creative, categorizing objects, orientation, and team qiuz.~small group intervention (8-12 per group), total number of group is 5.
Study NCT02126059 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aroma-massage
Description: Researcher will conduct hand and arm massage to a patient, once a week, each time session for 30 mins with natural tested and safe aroma-essential oil.
Study NCT01878630 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Patient Management
Description: Guideline-based care in heart failure including at least 5 scheduled doctor's visits within 12 months (GP and specialist) plus devices for Remote Patient Management at patient site for daily monitoring of ECG, weight, blood pressure, self-report of health status:~* weighing scale (Seca 861 with bluetooth, seca gmbh \& co. kg.)~* blood pressure device (UA767PBT with bluetooth, A\&D Ltd.)~* ECG-eventrecorder (PhysioMem® PM 1000, getemed Medizin- und Informationstechnik AG)~* patient-communication platform (Physio-Gate® PG 1000, getemed Medizin- und Informationstechnik AG)~* help call device (DORO Easy 510/ Doro HandlePlus 334gsm, doro AB)~at center site:~- electronic patient record (eHealth connect 2.0, T-Systems International)
Study NCT01878630 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Guideline-based care in heart failure including at least 5 scheduled doctor's visits within 12 months (GP and specialist)
Study NCT01211912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 1 (20 patients)
Description: Acetaminophen 1000 mg by mouth once
Study NCT01211912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 2 (34 patients)
Description: Acetaminophen 1000 mg by mouth once